英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Keppel查看　Keppel　在百度字典中的解释百度英翻中〔查看〕
Keppel查看　Keppel　在Google字典中的解释Google英翻中〔查看〕
Keppel查看　Keppel　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA Approves Inluriyo for ESR1-Mutated Advanced Breast Cancer . . .
    The FDA has approved Eli Lilly’s Inluriyo (imlunestrant), the first oral estrogen receptor antagonist for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, based on Phase III EMBER-3 results showing a 38% reduction in risk of progression or death versus endocrine therapy
  • ORSERDU™ (elacestrant): The First and Only Therapy Indicated . . .
    ORSERDU (elacestrant) 345 mg tablets are indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Please see full Prescribing Information, including Patient Information
  • FDA approves elacestrant for ER-positive, HER2-negative, ESR1 . . .
    On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc ) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1
  • U. S. FDA approves Inluriyo (imlunestrant) for adults with ER+ . . .
    Inluriyo is a treatment for ER+, HER2–, ESR1-mutated MBC Some breast cancers develop ESR1 mutations that can cause estrogen receptors to become overactive and drive cancer growth
  • EMERALD Trial for ESR1-Mutations | ORSERDU® (elacestrant)
    INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • New Drug Approved to Treat Metastatic Breast Cancer Patients . . .
    ORSERDU, an oral once-daily medication, is approved for women who have gone through menopause and adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, whose disease has progressed after endocrine therapy
  • ESR1-Mutation Resources | ORSERDU® (elacestrant)
    INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • ELEVATE Trial: Elacestrant Combos Boost PFS in ER+ HER2 . . .
    Study Rationale In January 2023, the FDA approved elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy 2
  • HCP Home | Inluriyo™ (imlunestrant)
    Indication Inluriyo ™ is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy 1
  • Inluriyo™ (imlunestrant)
    Inluriyo is a targeted treatment for ER+, HER2–, ESR1 -mutated MBC Some breast cancers have an ESR1 mutation that leads to overactive estrogen receptors that fuel the growth and division of cancer cells The FDA approval is based on the results of the EMBER-3 trial in the patient population harboring ESR1 -mutated MBC (n=256)





中文字典-英文字典  2005-2009